The Federal Circuit has nullified a $9.1 million attorney fee award that was previously granted to Elysium Health Inc. This award originated from a patent infringement lawsuit initiated by ChromaDex and Dartmouth College. The appellate court decided that the district judge involved did not perform an adequate analysis regarding the patent eligibility in question. This decision marks a significant turn in the ongoing litigation between these healthcare entities. More details can be found on Law360.
The case has roots in a dispute over a patented nicotinamide riboside compound, a chemical meant to boost cellular health, that ChromaDex alleged Elysium infringed upon. The lower court had previously ruled in favor of Elysium, awarding the substantial attorneys’ fee on the grounds of litigation misconduct by ChromaDex. This decision came after findings suggesting a strategic misuse of the legal system to drain Elysium’s resources.
The Federal Circuit’s reversal centers on the determination that the patent’s validity issues were not thoroughly vetted under the standards established in Alice Corp. v. CLS Bank International. This ruling is pivotal as it serves as a reminder of the essential need for robust patent eligibility scrutiny in intellectual property disputes.
Importantly, this decision may have broader implications for similar patent litigation cases, indicating a potential recalibration of how fee awards are assessed. For those in corporate legal departments and law firms, especially those specializing in intellectual property law, staying abreast of such evolving jurisprudence is crucial. It signals the courts’ continuous re-evaluation of patent eligibility related to technological and scientific advancements.
The appellate court’s resolution sends the case back to the district court for further proceedings, potentially altering legal strategies for both ChromaDex and Elysium moving forward. Legal analysts will undoubtedly be monitoring the case closely as it unfolds, providing further insights into how such disputes might be resolved in the future.